BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
July 24, 2003
View Archived Issues
Novartis, Cell Genesys Enter $28.5M Oncolytic Virus Deal
About five months after curtailing its gene therapy efforts in favor of other programs, Cell Genesys Inc.'s move has paid off in the form of a $28.5 million deal with Novartis AG to develop oncolytic virus products. (BioWorld Today)
Read More
Micrologix Takes Hit On Failed Phase III Blood Infection Trial
Read More
Disrupted Hox Fetal Mouse Genes Implicated In Global Patterning Of Appendicular Skeleton Formation
Read More
Amgen Beats Earnings Forecast, Increases Full-Year EPS Guidance
Read More
Other News To Note
Read More
Appointments And Advancements
Read More